media – Page 4 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

KOREA CHEM

Organiser：Kyungyon Exhibition Company, South Korea Time：March 31–April 3, 2026 Address：KINTEX (Korea International Exhibition Center) Exhibition hall：217-59 Kintekseu-ro, Daehwa-dong, Ilsanseo-gu, Goyang-si, Gyeonggi-do, South Korea Product range: Oil and Powder Processing & Chemical Machinery: Dryers, granulators, mixers, concentrators, sterilizers, agitators, reactors, dough mixers, incubators, valves, classifiers, blenders, industrial boilers, separators, washing machines, sterilization equipment, sludge collectors, spray dryers, compressors, filtration systems, heat exchangers, conveyors, mills, evaporators, vibrators, extractors, dehydrators, deodorizers, antifoaming agents, stirrers Engineering Materials & Components: Nickel, fluoropolymers, silicones, epoxy resins, adhesive tapes, Teflon, special/non-ferrous metals, specialty rubbers, titanium, alloys, synthetic resins, environmental control and safety equipment Environmental Control & Safety Equipment: Process safety, explosion-proof equipment, industrial protection, firefighting equipment Power Transmission Systems: Gear reducers, motors, gearboxes, frequency converters, couplings Control Equipment & Systems: Process control, sensors, pressure gauges, thermometers, flow meters, material testing instruments, viscometers Plant Engineering & System Design: Measuring instruments, condensers, feeding devices, dust collectors, filling and ...
- Source: drugdu
- 50
- December 25, 2025
Over $2 billion! Another major deal for a domestically developed innovative drug

Today, Tongyi Pharmaceuticals announced that it has entered into an exclusive licensing agreement with MultiValent for CBP-1018, a peptide-drug conjugate for the treatment of prostate cancer . Under the terms of the agreement, MultiValent will obtain exclusive rights to develop and commercialize CBP-1018 in markets outside of Greater China. Tongyi Pharmaceuticals will receive an upfront payment of US$20 million, a 20% equity stake in MultiValent, and up to approximately US$2 billion in future payments for development, regulatory, and commercial milestones, as well as tiered sales royalties. CBP-1018 is a bispecific peptide drug developed by Yimei Pharmaceuticals based on its proprietary Bi-XDC (bispecific dual-ligand conjugate) platform. It is conjugated with Auristatin-E and targets two proteins highly expressed in prostate cancer cells: PSMA and FRα . In a phase I/II clinical trial involving more than 110 patients with metastatic castration-resistant prostate cancer, intravenous CBP-1018 demonstrated encouraging preliminary safety and efficacy. A median ...
- Source: drugdu
- 50
- December 24, 2025
Good news for middle-aged and elderly men! Taincon has become the first generic version of a compound drug for benign prostatic hyperplasia

Recently, according to information published on the official website of the National Medical Products Administration (NMPA), Shandong Huabo Kaisheng Biotechnology, a wholly-owned subsidiary of Guangdong Taienkang, has received approval for the marketing of finasteride tadalafil capsules (trade name: Aitinglie® ) , successfully becoming the first generic version of this drug in China. The original drug was developed by VERU in the United States and approved there in 2021. This domestic production fills a market gap for compound treatment drugs for benign prostatic hyperplasia in China . The unique feature of finasteride tadalafil capsules lies in the synergistic effect of its dual mechanisms of action . • Finasteride, as a type II 5α-reductase inhibitor, can inhibit benign prostatic hyperplasia at its source by reducing the gland size by lowering dihydrotestosterone levels; • Tadalafil, as a PDE5 inhibitor, quickly relieves urinary difficulties by relaxing smooth muscles. This combination achieves both symptomatic and ...
- Source: drugdu
- 51
- December 24, 2025
BeiGene – Catadegbrutinib Initiates International Multicenter Phase II Clinical Trial for B-Cell Leukemia

On December 23, 2025, BeiGene announced the initiation of a global, multicenter Phase II clinical trial of catadegbrutinib (BTK, PROTAC) for B-cell hematologic malignancies. The trial, designated CTR20254960, is titled “Evaluating BGB-16673, a Bruton’s tyrosine kinase-targeting protein degrader, in a Phase 1/2, open-label, dose-escalation and expansion study for the treatment of patients with B-cell malignancies.” This international, multicenter clinical trial plans to enroll 730 participants. The investigational drug in this clinical trial is catadegbrutinib. The primary endpoint was the major response rate (MRR) in stage II. The domestic lead institution is Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and the principal investigator is Professor Li Jian. https://bydrug.pharmcube.com/news/detail/55a4c0369a540aa555859fb702eea4f7
- Source: drugdu
- 48
- December 24, 2025
IND for Oral Small-Molecule KRAS G12D Inhibitor ABSK141 Approved by NMPA

On the morning of December 24, Abbisko Therapeutics announced on the Hong Kong Stock Exchange that its subsidiary, Shanghai Abbisko Biotechnology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) of China for the Investigational New Drug (IND) application of its oral, highly potent, and selective small-molecule KRAS G12D inhibitor ABSK141. The drug is intended for the treatment of patients with advanced solid tumors harboring the KRAS G12D mutation. Reference：https://finance.eastmoney.com/a/202512243600135972.html
- Source: drugdu
- 43
- December 24, 2025
Wantai Bio’s bivalent HPV vaccine (Escherichia coli) was shortlisted for the National Immunization Program (NIP)

Beijing Business Today — On the evening of December 22, Wantai Bio (603392.SH) announced that its wholly-owned subsidiary, Xiamen Innovax Biotech Co., Ltd., participated in the bidding for the 2025 National Immunization Program (NIP) Vaccine Centralized Procurement Project—specifically for the Bivalent Human Papillomavirus (HPV) Vaccine. The company’s Bivalent HPV Vaccine (E. coli) has been shortlisted with a unit price of 27.5 RMB. Wantai Bio stated that this centralized procurement is organized by the Chinese Center for Disease Control and Prevention (China CDC). If the company subsequently signs the procurement contract and organizes production and supply, it will help expand the sales volume of the shortlisted product, increase its market share, promote domestic market development, and enhance the company’s brand influence. https://finance.eastmoney.com/a/202512223598332095.html
- Source: drugdu
- 43
- December 24, 2025
Subsidiary Receives Clinical Trial Approval for Daratumumab Injection

China Securities Intelligent Financial News — CSPC NovaWise (300765.SZ) announced on the evening of December 23 that its majority-owned subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration (NMPA) for its Daratumumab Injection. The drug will commence domestic clinical trials in the near future. According to the announcement, the injection is a recombinant all-human IgG1 monoclonal antibody targeting ADP-ribosyl cyclase (CD38). As a biosimilar to the originator drug DARZALEX®, it was filed under Category 3.3 for therapeutic biological products and is indicated for the treatment of adult patients with multiple myeloma. The development of this product follows the guiding principles for biosimilar research. Results from pharmaceutical and non-clinical studies demonstrate that the product is highly similar to the reference originator drug in terms of quality, safety, and efficacy, supporting the progression to subsequent clinical studies. Public records show ...
- Source: drugdu
- 38
- December 24, 2025
Walvax Bio’s subsidiary’s HPV vaccine selected for national centralized procurement

On December 23, Walvax Bio(300142) issued an announcement stating that its subsidiary participated in the National Immunization Program’s centralized procurement project for vaccines and successfully entered the shortlist. The announcement shows that Yuxi Zerun Biotechnology Co., Ltd.’s bivalent human papillomavirus vaccine (Pichia pastoris) was shortlisted for the project, with a shortlisted unit price of 27.5 yuan. This vaccine is primarily used to prevent diseases caused by high-risk HPV types 16 and 18, including cervical cancer. It was launched in China in 2022 and received prequalification from the World Health Organization in August 2024. This inclusion in the list will help expand the company’s sales of its bivalent HPV vaccine, increase market coverage, promote the market development of related products, and enhance brand influence. However, the announcement also pointed out that since only two companies were shortlisted, further negotiations with various provinces are needed, and the implementation period for vaccination is relatively ...
- Source: drugdu
- 42
- December 24, 2025
Jacobio secured the largest licensing deal for a clinical-stage small molecule anticancer drug, yet its stock price plummeted by over 13%. The chairman responded

“US$2.015 billion is, according to our statistics, the largest overseas licensing collaboration for small molecule anticancer drugs in the clinical stage in China.” On the morning of December 22, Jacobio (HK01167) held an online communication meeting regarding its newly announced business development (BD) efforts surrounding the pan-KRAS inhibitor JAB-23E73. Simultaneously, the company’s stock price fell by over 10%, closing down 13.58%. Both the transaction amount and AstraZeneca’s position in the oncology drug field have generated considerable excitement among investors who saw the news of the collaboration the night before. Moreover, this is Jacobio’s first business development (BD) deal announced this year. Was the secondary market’s reaction unexpected? At the communication meeting, Wang Yinxiang, Chairman of Jacobio, responded to this question from a reporter from the Daily Economic News. He said that as a biotech company, Jacobio pays attention to the secondary market, but it cannot be “led by the crowd” ...
- Source: drugdu
- 41
- December 24, 2025
Quanxin Biotech Reaches Licensing Agreement for QX027N, Targeting Asthma and Atopic Dermatitis

On December 22, Quanxin Biotech (02509) issued an announcement stating that it has entered into a licensing and collaboration agreement with LE2025 Therapeutics AG, a subsidiary of Windward Bio Group AG, authorizing it to exclusively develop and commercialize QX027N globally (excluding Mainland China, Taiwan, Hong Kong SAR and Macau SAR). In return, the company will be entitled to receive payments of up to $700 million, including upfront payments, equity in Windward Bio, development and commercial milestone payments, and tiered royalties based on net sales of QX027N in licensed territories. QX027N is a long-acting anti-TSLPxIL-13 bispecific antibody independently developed by the company. It successfully initiated a Phase I clinical trial on December 12, 2025, and completed the enrollment of the first subject. This antibody is intended for the treatment of asthma and atopic dermatitis and has received implied approval for clinical trials from the Center for Drug Evaluation of the National ...
- Source: drugdu
- 40
- December 24, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.